Johann De Bono
Institute of Cancer Research, United Kingdom · The Royal Marsden NHS FT\The Institute of Cancer Research · National Health Service, United Kingdom
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Johann De Bono as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:34 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07737509 · Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample AnalysisInstitute of Cancer Research, United Kingdom · recruiting · Advanced Solid Tumours · study director
- Ph1/Ph2NCT07002320 · Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate CancerInstitute of Cancer Research, United Kingdom · recruiting · Metastatic Castrate-Resistant Prostate Cancer (mCRPC) · study director
- N/ANCT06423976 · Microbiome Molecular CharaterisationInstitute of Cancer Research, United Kingdom · recruiting · Prostate Cancer · principal investigator
- Ph1/Ph2NCT06126731 · Combination Study of Antibiotics With Enzalutamide (PROMIZE)Institute of Cancer Research, United Kingdom · recruiting · Metastatic Castration-Resistant Prostate Cancer (mCRPC) · principal investigator
- Ph1/Ph2NCT05272709 · TT-702 in Patients With Advanced Solid Tumours.Cancer Research UK · recruiting · Advanced Solid Tumors · principal investigator
- Ph1/Ph2NCT05057013 · A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid TumoursCancer Research UK · active not recruiting · Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer · principal investigator
- Ph1/Ph2NCT04458311 · Abiraterone Acetate in Combination With TildrakizumabInstitute of Cancer Research, United Kingdom · terminated · Metastatic Castration Resistant Prostate Cancer · study director
- N/ANCT03934164 · Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTROInstitute of Cancer Research, United Kingdom · unknown · Metastatic Prostate Cancer, Castration-resistant Prostate Cancer · principal investigator
- Ph1/Ph2NCT03568656 · Study to Evaluate CCS1477 in Advanced TumoursCellCentric Ltd. · completed · Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer · principal investigator
- Ph2NCT03506997 · Trial of Pembrolizumab in Metastatic Castration Resistant Prostate CancerInstitute of Cancer Research, United Kingdom · unknown · Castration-resistant Prostate Cancer · principal investigator
- Ph3NCT03327662 · Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate CancerInstitute of Cancer Research, United Kingdom · terminated · Adenocarcinoma of the Prostate · principal investigator
- Ph1/Ph2NCT03177187 · Combination Study of AZD5069 and Enzalutamide.Institute of Cancer Research, United Kingdom · terminated · Metastatic Castration Resistant Prostate Cancer · principal investigator
- Ph1/Ph2NCT03035591 · ODM-207 in Patients With Advance Solid TumoursOrion Corporation, Orion Pharma · completed · Solid Tumors · principal investigator
- Ph3NCT02987543 · Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)AstraZeneca · completed · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph1/Ph2NCT02552121 · Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsSeagen Inc. · completed · Ovary Cancer, Cervix Cancer, Endometrium Cancer · principal investigator
- Ph2NCT02525068 · A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPCInstitute of Cancer Research, United Kingdom · unknown · Adenocarcinoma of the Prostate · principal investigator
- Ph1/Ph2NCT02042885 · A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced CancerOtsuka Novel Products GmbH · terminated · Prostate Cancer, Salivary Gland Cancer, Endometrial Cancer · principal investigator
- Ph1/Ph2NCT02001623 · Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsSeagen Inc. · completed · Ovary Cancer, Cervix Cancer, Endometrium Cancer · principal investigator
- Ph1/Ph2NCT01792310 · A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid TumoursLaminar Pharmaceuticals · completed · Glioma, Other Solid Tumours · study chair
- Ph2NCT01682772 · TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate CancerInstitute of Cancer Research, United Kingdom · unknown · Adenocarcinoma of the Prostate · principal investigator
- Ph1NCT01337518 · A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate CancerEnzon Pharmaceuticals, Inc. · suspended · Prostatic Neoplasm · principal investigator
- Ph3NCT01188187 · Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate CancerAchieve Life Sciences · completed · Prostate Cancer · study chair
- Ph1NCT00794131 · Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid TumorsGenelux GmbH · completed · Advanced Cancers (Solid Tumors) · principal investigator
- Ph1NCT00748891 · DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)AstraZeneca · completed · Cancer · principal investigator
- Ph1NCT00516724 · Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or PaclitaxelAstraZeneca · completed · Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin · principal investigator
- Ph1NCT00516373 · A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)AstraZeneca · completed · Ovarian Neoplasms, BRCA1 Protein, BRCA2 Protein · principal investigator
- Ph2NCT00299351 · A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.Royal Marsden NHS Foundation Trust · unknown · Peripheral T Cell Lymphoma (PTCL) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:34 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed
- 35 citationsRCR 1.0